Evidence map›Paper›PMID 27600045›Full record

ArticleAntimicrobial agents and chemotherapy2016

Transport of Azithromycin into Extravascular Space in Rats.

Shinji Kobuchi, Miki Aoki, Chiaki Inoue, Hiroyuki Murakami, Akiko Kuwahara, Tsutomu Nakamura, Hiroyuki Yasui, Yukako Ito, Kanji Takada, Toshiyuki Sakaeda

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Shinji KobuchiDepartment of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Miki AokiDepartment of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Chiaki InoueDepartment of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Hiroyuki MurakamiCenter for Integrative Education in Pharmacy and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Akiko KuwaharaSchool of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.
Tsutomu NakamuraEducation and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Nasahara, Takatsuki, Osaka, Japan.
Hiroyuki YasuiDepartment of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan.
Yukako ItoDepartment of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Kanji TakadaBioSerenTach Inc., Kyoto, Japan.
Toshiyuki SakaedaDepartment of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan sakaedat@mb.kyoto-phu.ac.jp.
Kyoto Pharmaceutical University · JPKyoto University · JPMukogawa Women's University · JPOsaka University of Pharmaceutical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent clinical trials showed a prolonged retention of subinhibitory concentrations of unbound azithromycin in the interstitial fluid of soft tissues despite the fact that azithromycin is extensively distributed in tissues. In these clinical trials, interstitial fluid samples were obtained by using the microdialysis method, and it was established that drug concentrations represent protein-unbound drug concentrations. The present study was designed to measure total azithromycin concentrations in the interstitial fluid of the skin of rats by directly collecting interstitial fluid samples from a pore formed on the skin by a dissolving microneedle array. The total azithromycin concentrations in interstitial fluid of the skin were about 4 to 5 times higher than those in plasma throughout the experimental period, and stasis of the azithromycin concentration in interstitial fluid was observed when the concentration of azithromycin in plasma was at the lower limit of quantification. In addition, the skin/plasma concentration ratio transiently increased after dosing (from 4.3 to 83.1). Our results suggest that azithromycin was trapped inside white blood cells and/or phagocytic cells in not only blood but also interstitial fluid, resulting in a high total azithromycin concentration and the retention of its antimicrobial activity at the primary infection site. The stasis of azithromycin in interstitial fluid and skin would lead to long-lasting pharmacological effects (including those against skin infection) at concentrations exceeding the MIC.

Indexed as

Administration, IntravenousAnimalsAnti-Bacterial AgentsAzithromycinBiological TransportDrug MonitoringExtracellular FluidMaleNeedlesRats, WistarSkinTissue DistributionAnti-Bacterial AgentsAzithromycin

Identifiers

PMID27600045
PMCPMC5075091
OpenAlexW2511526184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.